Stockscreener 앱 받기
4.80
0.00%
0.00
시장 영업 전:
4.70
-0.10
-2.08%
전일 마감가:
$4.80
열려 있는:
$4.68
하루 거래량:
135.41K
Relative Volume:
0.01
시가총액:
$16.86M
수익:
-
순이익/손실:
$-37.75M
주가수익비율:
-1.4769
EPS:
-3.25
순현금흐름:
$-30.91M
1주 성능:
-32.49%
1개월 성능:
+1,230%
6개월 성능:
+1,304%
1년 성능:
+100.84%
1일 변동 폭
$4.65
$4.93
1주일 범위
$4.36
$5.3995
52주 변동 폭
$0.224
$10.19
Cellectar Biosciences Inc Stock (CLRB) Company Profile
명칭
Cellectar Biosciences Inc
전화
(608) 441-8120
주소
100 CAMPUS DRIVE, FLORHAM PARK, NJ
CLRB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
4.80 | 16.86M | 0 | -37.75M | -30.91M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.41 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
538.11 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.13 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
546.04 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
240.99 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-05 | 재개 | Ladenburg Thalmann | Buy |
| 2020-07-01 | 개시 | Oppenheimer | Outperform |
| 2020-01-21 | 재개 | ROTH Capital | Buy |
| 2019-09-13 | 개시 | ROTH Capital | Buy |
| 2016-12-21 | 개시 | Ladenburg Thalmann | Buy |
Cellectar Biosciences Inc 주식(CLRB)의 최신 뉴스
Cellectar Biosciences announces one-for-thirty reverse stock split - MarketScreener
Cellectar Biosciences (CLRB) Announces One-for-Thirty Reverse St - GuruFocus
Cellectar Biosciences announces 1:30 reverse stock split - Investing.com
Cellectar Biosciences (CLRB) Announces Reverse Stock Split | CLR - GuruFocus
Cellectar Biosciences Reports 1-for-30 Reverse Stock Split, Effective June 24 - marketscreener.com
Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split | CLRB Stock News - GuruFocus
Cellectar Biosciences, Inc. Announces One-for-Thirty Reverse Stock Split Effective June 24, 2025 - Nasdaq
Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split - GlobeNewswire
Roth Capital Issues Positive Estimate for CLRB Earnings - Defense World
Cellectar Biosciences Approves Reverse Stock Split Proposal - TipRanks
Cellectar Biosciences (CLRB) Reports Promising Phase 1 Trial Res - GuruFocus
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 - GlobeNewswire
Cellectar reports improved survival in pediatric brain tumor trial By Investing.com - Investing.com India
Cellectar reports improved survival in pediatric brain tumor trial - Investing.com
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma - The Manila Times
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma | CLRB Stock News - GuruFocus
Breakthrough: New Drug Doubles Survival Time in Aggressive Childhood Brain Cancer Trial - Stock Titan
Squarepoint Ops LLC Makes New Investment in Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Defense World
Cellectar Biosciences announces $2.5 million stock sale By Investing.com - Investing.com India
Cellectar Biosciences Enters into Common Stock Agreements to Rai - GuruFocus
Cellectar Biosciences Expects to Raise $2.5 Million via Stock Sale, Warrant Exercise - marketscreener.com
Cellectar Biosciences (CLRB) Secures $2.5 Million from Stock Sal - GuruFocus
Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year? - Yahoo Finance
Cellectar Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
Cellectar Biosciences (CLRB) Secures $2.5M Through Stock Sale Agreements | CLRB Stock News - GuruFocus
Cellectar Biosciences announces $2.5 million stock sale - Investing.com Australia
Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules | CLRB Stock News - GuruFocus
Cellectar Biosciences Enters into Common Stock Agreements - GlobeNewswire
Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules - Yahoo Finance
FDA Designation Sparks Rally For This Biotech - The Globe and Mail
Cellectar Biosciences stock soars on FDA breakthrough designation - Investing.com Australia
Cellectar Biosciences stock soars on FDA breakthrough designation By Investing.com - Investing.com Canada
Cellectar Biosciences Stock Price, Quotes and Forecasts | NASDAQ:CLRB - Benzinga
Cellectar Biosciences (CLRB) Secures Breakthrough Therapy Designation | CLRB Stock News - GuruFocus
What's Behind Cellectar Biosciences' Stock Surge? FDA Update Explained - Yahoo Finance
US Stocks Higher; Dollar Tree Shares Plunge After Q1 Earnings - Benzinga
Cellectar Granted U.S. FDA Breakthrough Therapy Designation - GlobeNewswire
Cellectar Biosciences Says FDA Granted Breakthrough Therapy Designation for Experimental Cancer Drug; Shares Rise Pre-Bell - marketscreener.com
Cellectar Biosciences (CLRB) Gains FDA Breakthrough Therapy Desi - GuruFocus
Cellectar Biosciences Announces Breakthrough Therapy Designation for iopofosine I 131, Reports 83.6% Overall Response Rate from CLOVER WaM Phase 2 Study - Nasdaq
Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM) - Quantisnow
Zacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies - Yahoo Finance
CVM Stock Offering Priced Below Previous Closing Value | CVM Stock News - GuruFocus
Cellectar Biosciences (NASDAQ:CLRB) Now Covered by StockNews.com - Defense World
Cellectar signals Q3 EMA decision for conditional iopofosine approval while advancing pipeline and exploring strategic alternatives - MSN
Analysts Update Their Estimates For Cellectar Biosciences Inc - Stocksregister
Cellectar Biosciences’ (CLRB) “Hold” Rating Reiterated at Maxim Group - Defense World
Roth Capital Brokers Increase Earnings Estimates for CLRB - Defense World
Cellectar Biosciences Earnings Call: Progress Amid Challenges - TipRanks
Cellectar Biosciences (CLRB) Downgraded to 'Hold' by Maxim Group - GuruFocus
StockNews.com Initiates Coverage on Cellectar Biosciences (NASDAQ:CLRB) - Defense World
Cellectar Biosciences Inc (CLRB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Cellectar Biosciences Inc 주식 (CLRB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Longcor Jarrod | Chief Operating Officer |
Jul 02 '25 |
Buy |
4.99 |
10,000 |
49,900 |
12,768 |
| Kolean Chad J | Chief Financial Officer |
Jul 02 '25 |
Buy |
4.99 |
5,000 |
24,950 |
6,418 |
| Longcor Jarrod | Chief Operating Officer |
Jan 10 '25 |
Buy |
0.28 |
30,000 |
8,400 |
83,141 |
1.08%
2.14%
자본화:
|
볼륨(24시간):